SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$45.53 USD
+1.33 (3.01%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $45.55 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for SpringWorks Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -325.10 | -277.42 | -173.91 | -45.57 | -58.31 |
Depreciation/Amortization & Depletion | 1.67 | 0.77 | 0.49 | 0.35 | 0.19 |
Net Change from Assets/Liabilities | -0.58 | 38.10 | 5.12 | 1.35 | 4.95 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 101.23 | 76.99 | 40.43 | 11.69 | 5.72 |
Net Cash From Operating Activities | -222.80 | -161.56 | -127.88 | -32.19 | -47.44 |
Property & Equipment | -7.39 | -10.20 | -2.02 | -0.64 | -0.67 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 42.14 | -205.40 | 85.61 | -418.19 | -3.59 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 34.75 | -215.60 | 83.59 | -418.83 | -4.26 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -2.66 | 56.09 | 1.16 | 0.89 | 0.02 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 299.30 | 284.61 | 0.00 | 269.59 | 333.69 |
Net Cash from Financing Activities | 296.64 | 340.70 | 1.16 | 270.49 | 333.71 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 108.60 | -36.46 | -43.13 | -180.54 | 282.00 |
Cash at Beginning of Period | 68.07 | 104.53 | 147.65 | 328.19 | 46.19 |
Cash at End of Period | 176.67 | 68.07 | 104.53 | 147.65 | 328.19 |
Diluted Net EPS | -5.15 | -5.21 | -3.59 | -1.05 | -3.81 |
Fiscal Year End for SpringWorks Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -325.10 | -230.78 | -151.35 | -73.42 |
Depreciation/Amortization & Depletion | NA | 1.67 | 1.13 | 0.64 | 0.25 |
Net Change from Assets/Liabilities | NA | -0.58 | -4.28 | -8.20 | -13.61 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 101.23 | 73.85 | 49.29 | 24.96 |
Net Cash From Operating Activities | NA | -222.80 | -160.09 | -109.63 | -61.82 |
Property & Equipment | NA | -7.39 | -9.69 | -6.07 | -2.98 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 42.14 | 203.65 | 165.43 | 101.58 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 34.75 | 193.96 | 159.36 | 98.60 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -2.66 | -2.43 | -2.19 | -1.85 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 299.30 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 296.64 | -2.43 | -2.19 | -1.85 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 108.60 | 31.44 | 47.54 | 34.94 |
Cash at Beginning of Period | NA | 68.07 | 68.07 | 68.07 | 68.07 |
Cash at End of Period | NA | 176.67 | 99.51 | 115.61 | 103.01 |
Diluted Net EPS | NA | -1.45 | -1.27 | -1.25 | -1.18 |